5.4 References
［1］Bahl JJ，De Armond RL，Bressler R.Multisite inhibition by phenylacetate of PC-3 cell growth.Anticancer Drugs，2004，15（5）：513-523.
［2］刘敬东，范希文，郑兴厂，等.肺炎并急性心力衰竭患儿血清脂肪酸结合蛋白变化的意义.中国误诊学杂志，2008，6（18）：4339-4340.
［3］Gianni L，Pienkowski T，Im Y H，et al.5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced，inflammatory，or early-stage HER2-positive breast cancer（Neo-Sphere）：a multicentre，open-label，phase 2 randomised trial［J］.Lancet Oncology，2016，13（1）：25-32.
［4］Gianni L，Pienkowski T，Im Y H，et al.Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced，inflammatory，or early HER2-positive breast cancer（NeoSphere）：a randomised multicentre，open-label，phase 2 trial［J］.Lancet Oncol，2012，13（1）：25-32.
［5］von Minckwitz G，Procter M，de Azambuja E，et al.Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer［J］.New England Journal of Medicine，2017，377（2）：122-131.(https://www.daowen.com)
［6］Schmid P.ESMO 2018 presidential symposium-IMpassion130：atezolizumab+nab-paclitaxel in triple-negative breast cancer.ESMO Open，2018，3（6）：e000453.
［7］Robson M，Im S A，Senkus E，et al.Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation［J］.New England Journal of Medicine，2017，377（6）：523.
［8］Zhang P，Tao S，Zhang Q，et al.Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes：a multicentre，open-label，superiority，phase 3，randomised controlled trial［J］.Lancet Oncology，2017，18（3）：371-383.
［9］Verma S，Miles D，Gianni L，et al.Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer［J］.New England Journal of Medicine，2013，368（25）：1783-1791.